ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase I for Idiopathic Hypersomnia (IH). According to GlobalData, Phase I drugs for Idiopathic Hypersomnia (IH) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALKS-2680’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALKS-2680 overview
It was under development for the treatment of disorders associated with excessive daytime sleepiness.
Synchronicity Pharma overview
Synchronicity Pharma discovers and develops novel therapies for the treatment of metabolic disorders, narcolepsy, and diabetes. The company has developed a proprietary platform which is designed to identify and characterize compounds that modulate the activity and function of molecular clocks and discovers drugs which modulate these clocks and clock-controlled systems. Synchronicity Pharma discovery programs include cryptochrome modulator programs and orexin modulator programs. The company conducts cryptochrome modulator programs to develop therapies for cushing’s syndrome and Type 2 diabetes; orexin modulator programs for narcolepsy and disorders associated with the excessive daytime sleepiness. Synchronicity Pharma is headquartered in San Francisco, California, the US.
For a complete picture of ALKS-2680’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
